• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

    2/26/26 6:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care
    Get the next $FTRE alert in real time by email

    Revenue and Adjusted EBITDA results delivered in line with stated full-year targets

    Full‑year cost savings exceeded previously communicated targets

    Highlights:

    • Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full year
    • Fourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 months
    • GAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full year
    • Adjusted EBITDA of $54.0 million for the fourth quarter and $189.9 million for the full year
    • Adjusted net income of $9.2 million, or $0.09 per diluted share for the fourth quarter; $40.4 million, or $0.43 per diluted share for the full year

    DURHAM, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the fourth quarter and full year ended December 31, 2025.

    "We finished 2025 with solid results for the fourth quarter, as the Fortrea team's shared commitment to commercial, operational and financial excellence becomes embedded in our way of working," said Anshul Thakral, CEO of Fortrea. "After a challenging first half of the year, we delivered a second half of strong book-to-bills. I'm proud not only of what we achieved but also how we achieved it. Our large pharma and biotech clients are giving our project teams very positive feedback across the board, as we work to meet and exceed their expectations every day. At the same time, we strengthened our balance sheet through disciplined capital allocation and continued debt paydown. We have continued to deliver and innovate, beginning the new year on strong footing for our journey back to growth and margin expansion."



    All commentary in this press release relates to continuing operations unless otherwise noted.

    Fourth Quarter 2025 Financial Results

    Revenue for the fourth quarter was $660.5 million, compared to $697.0 million in the fourth quarter of 2024.

    Fourth quarter GAAP net loss was $(32.5) million and diluted loss per share was $(0.35) compared to fourth quarter of 2024 GAAP net loss of $(73.9) million and diluted loss per share of $(0.82). Fourth quarter adjusted net income was $9.2 million and diluted income per share was $0.09 compared to fourth quarter of 2024 adjusted net income of $16.6 million and diluted income per share of $0.18. Fourth quarter adjusted EBITDA was $54.0 million, compared to fourth quarter of 2024 adjusted EBITDA of $56.0 million.

    Fortrea's book-to-bill ratio was 1.14x for the fourth quarter of 2025.

    Full Year 2025 Financial Results

    Revenue for the full year was $2,723.4 million, compared to $2,696.4 million for the full year 2024.

    Full year GAAP net loss was $(986.2) million and diluted loss per share was $(10.81), inclusive of a non-cash goodwill impairment charge of $797.9 million recognized in the first half of 2025, which impacted diluted loss per share by $(8.75), compared to 2024 GAAP net loss of $(271.5) million and diluted loss per share of $(3.03). Full year adjusted net income, which excludes the goodwill impairment and other charges, was $40.4 million and diluted income per share was $0.43 compared to 2024 adjusted net income of $30.1 million and diluted income per share of $0.33. Full year adjusted EBITDA was $189.9 million, compared to 2024 adjusted EBITDA of $202.5 million.

    The goodwill impairments occurred during the first half of 2025 and primarily resulted from declines in the Company's share price, as well as a macroeconomic market-driven increase to the discount rate. There were no indicators of impairment in the fourth quarter of 2025.

    Fortrea's trailing twelve-month book-to-bill ratio was 1.02x and backlog as of December 31, 2025, was $7,728.0 million.

    The Company's cash and cash equivalents were $174.6 million, and gross debt was $1,066.3 million as of December 31, 2025. For the full year ended December 31, 2025, operating cash flow was $113.5 million, and free cash flow was $88.3 million.

    2026 Financial Guidance

    For the full year 2026, the Company targets revenues in the range of $2,550 million to $2,650 million and adjusted EBITDA in the range of $190 million to $220 million.

    The guidance assumes foreign currency exchange rates as of December 31, 2025, remain in effect for the forecast period.

    The Company's 2026 financial guidance will be discussed during the Earnings Call at 8:00 am ET on February 26, 2026.

    Earnings Call and Replay

    Fortrea will host a conference call at 8:00 am ET on February 26, 2026, to review its financial results, provide 2026 financial guidance, and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link. A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations section of the Fortrea website. A supplemental slide presentation will also be available on the Investor Relations website prior to the start of the call.

    About Fortrea

    Fortrea (NASDAQ:FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company's 2026 financial guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "guidance," "expect," "assume," "anticipate," "intend," "plan," "forecast," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from the Company's expectations due to a number of factors, including, but not limited to, the following: the Company's dependence on third parties generally to provide services critical to its businesses; the Company's ability to successfully implement the Company's business strategies and execute the Company's long-term value creation strategy; risks and expenses associated with the Company's international operations, tariff policies, trade sanctions and other trade restrictions and currency fluctuations; the Company's customer or therapeutic area concentrations; the Company's adoption and use of technology within its business and the risks that the Company may not be able to capture the anticipated benefits of such technology or that such technology may have negative effects; the outcome and impact of pending or future litigation; any further deterioration in the macroeconomic environment, particularly within the pharmaceutical and biotechnology industry, or further changes in government regulations and funding, which could lead to defaults or cancellations by the Company's customers; the risk that the Company's backlog and net new business may not be indicative of the Company's future revenues and that the Company might not realize all of the anticipated future revenue reflected in the Company's backlog; the Company's ability to generate sufficient net new business awards, or if net new business awards are delayed, terminated, reduced in scope, or fail to go to contract; if the Company underprices its contracts, overruns its cost estimates, or fails to receive approval for, or experiences delays in documentation of change orders; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company's business, see the "Risk Factors" Section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company's subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company's filings with the SEC. Comparisons of results for current and any prior periods are not intended to express any future trends, or indications of future performance, unless expressed as such, and should only be viewed as historical data. All forward-looking statements are made only as of the date of this release and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments.

    Note on Non-GAAP Financial Measures

    This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States ("GAAP"), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Basic and Diluted EPS, and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the Company's financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the Company's financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the Company's results of operations as determined in accordance with GAAP.

    The Company uses non-GAAP measures in its operational and financial decision making and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. For example, in calculating Adjusted EBITDA, the Company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements and trademarks, trade names and other from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although the Company excludes amortization of acquired intangible assets from the Company's non-GAAP expenses, the Company believes that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income attributable to the Company. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The Company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

    The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for relevant definitions and reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. The Company's full-year 2026 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the Company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. Such items include, but are not limited to, acquisition-related expenses, restructuring and related expenses, goodwill impairment, stock-based compensation and other items not reflective of the Company's ongoing operations.

    Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the Company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the Company's results of operations as determined in accordance with GAAP.

    Fortrea Contacts

    Tracy Krumme (Investors) – 984-385-6707, [email protected] 

    Sue Zaranek (Media) – 919-943-5422, [email protected] 

    Kate Dillon (Media) – 646-818-9115, [email protected] 

     
    FORTREA HOLDINGS INC.

    CONSOLIDATED STATEMENTS OF OPERATIONS

    (in millions, except per share data)

    (unaudited)

     
     Three Months Ended

    December 31,
     Years Ended

    December 31,
     2025

     2024

     2025

     2024

    Revenues$660.5  $697.0  $2,723.4  $2,696.4 
    Costs and expenses:       
    Direct costs, exclusive of depreciation and amortization 529.4   556.1   2,219.6   2,162.2 
    Selling, general and administrative expenses, exclusive of depreciation and amortization 103.0   148.1   456.4   560.7 
    Depreciation and amortization 19.3   20.8   78.0   85.3 
    Goodwill and other asset impairments —   —   797.9   — 
    Restructuring and other charges 22.4   27.6   44.1   50.1 
    Total costs and expenses 674.1   752.6   3,596.0   2,858.3 
    Operating loss (13.6)  (55.6)  (872.6)  (161.9)
    Other income (expense):       
    Interest expense (23.2)  (21.9)  (91.4)  (123.8)
    Foreign exchange gain (loss) 1.2   (3.6)  (26.9)  (10.6)
    Other, net —   6.2   7.9   21.3 
    Loss from continuing operations before income taxes (35.6)  (74.9)  (983.0)  (275.0)
    Income tax (benefit) expense (3.1)  (1.0)  3.2   (3.5)
    Loss from continuing operations (32.5)  (73.9)  (986.2)  (271.5)
    Income (loss) from discontinued operations, net of tax —   12.7   —   (57.0)
    Net loss$(32.5) $(61.2) $(986.2) $(328.5)
            
    Earnings (loss) per common share       
    Basic and diluted earnings (loss) per share from continuing operations$(0.35) $(0.82) $(10.81) $(3.03)
    Basic and diluted earnings (loss) per share from discontinued operations —   0.14   —   (0.64)
    Basic and diluted earnings (loss) per share$(0.35) $(0.68) $(10.81) $(3.67)



    FORTREA HOLDINGS INC.

    CONSOLIDATED BALANCE SHEETS

    (dollars and shares in millions)

    (unaudited)

     
     December 31,

    2025
     December 31,

    2024
    ASSETS   
    Current assets:   
    Cash and cash equivalents$174.6  $118.5 
    Accounts receivable and unbilled services, net 589.7   659.5 
    Prepaid expenses and other 132.9   170.2 
       Total current assets 897.2   948.2 
    Property, plant and equipment, net 149.5   156.3 
    Goodwill, net 960.0   1,710.4 
    Intangible assets, net 622.0   655.7 
    Deferred income taxes 6.2   5.2 
    Other assets, net 80.8   103.4 
    Total assets$2,715.7  $3,579.2 
    LIABILITIES AND EQUITY   
    Current liabilities:   
    Accounts payable$29.7  $138.2 
    Accrued expenses and other current liabilities 395.8   369.8 
    Unearned revenue 473.8   353.3 
    Current portion of long-term debt 4.8   74.8 
    Short-term operating lease liabilities 9.2   13.4 
       Total current liabilities 913.3   949.5 
    Long-term debt, less current portion 1,048.0   1,049.7 
    Operating lease liabilities 54.0   60.6 
    Deferred income taxes and other tax liabilities 97.6   121.7 
    Other liabilities 39.3   35.3 
    Total liabilities 2,152.2   2,216.8 
    Commitments and contingent liabilities   
    Equity:   
    Common stock, 93.1 and 89.7 shares outstanding at December 31, 2025 and 2024, respectively 0.1   0.1 
    Additional paid-in capital 2,116.6   2,042.2 
    Accumulated deficit (1,383.2)  (397.0)
    Accumulated other comprehensive loss (170.0)  (282.9)
       Total equity 563.5   1,362.4 
    Total liabilities and equity$2,715.7  $3,579.2 



    FORTREA HOLDINGS INC.

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in millions)

    (unaudited)

     
     Years Ended

    December 31,
     2025

     2024

    CASH FLOWS FROM OPERATING ACTIVITIES:   
    Net loss$(986.2) $(328.5)
    Adjustments to reconcile net loss to net cash provided by operating activities:   
    Depreciation and amortization 78.0   86.9 
    Stock compensation 74.4   58.4 
    Credit loss expense 12.0   22.2 
    Operating lease right-of-use asset expense 11.5   14.0 
    Operating lease right-of-use asset impairment 1.3   4.8 
    Goodwill and other asset impairments 797.9   24.0 
    Deferred income taxes (32.0)  (24.6)
    Unrealized foreign exchange movements 36.4   (19.5)
    Loss on sale of business —   19.6 
    Write-off of debt issuance costs 1.0   12.2 
    Other, net 4.5   9.3 
    Changes in assets and liabilities:   
       Decrease in accounts receivable and unbilled services, net 70.9   309.9 
       Decrease (increase) in prepaid expenses and other 32.4   (78.1)
       (Decrease) increase in accounts payable (109.9)  7.2 
       Increase in deferred revenue 114.8   140.0 
       Increase in accrued expenses and other 6.5   5.0 
       Net cash provided by operating activities 113.5   262.8 
    CASH FLOWS FROM INVESTING ACTIVITIES:   
    Capital expenditures (25.2)  (25.5)
    Proceeds from sale of business, net 39.6   276.6 
    Proceeds from sale of assets —   0.5 
    Net cash provided by investing activities 14.4   251.6 
    CASH FLOWS FROM FINANCING ACTIVITIES:   
    Proceeds from revolving credit facilities 453.9   826.5 
    Payments on revolving credit facilities (453.9)  (826.5)
    Debt issuance costs (0.6)  (0.7)
    Principal payments on long-term debt (75.7)  (482.7)
    Payments for taxes related to net share settlement of stock awards —   (14.4)
    Net cash used for financing activities (76.3)  (497.8)
    Effect of exchange rate changes on cash and cash equivalents 4.5   (6.7)
    Net change in cash and cash equivalents 56.1   9.9 
    Cash and cash equivalents at beginning of period 118.5   108.6 
    Cash and cash equivalents at end of period$174.6  $118.5 
            

    The cash flows related to discontinued operations have not been segregated and are included in the consolidated statements of cash flows.

     
    RECONCILIATION OF NON-GAAP MEASURES

     
    FORTREA HOLDINGS INC.

    NET INCOME TO ADJUSTED EBITDA RECONCILIATION

    (in millions)

    (unaudited)

     
      Three Months Ended

    December 31,
     Years Ended

    December 31,
      2025

     2024

     2025

     2024

    Adjusted EBITDA from continuing operations:        
    Net loss from continuing operations $(32.5) $(73.9) $(986.2) $(271.5)
    Income tax (benefit) expense  (3.1)  (1.0)  3.2   (3.5)
    Interest expense, net  23.2   21.9   91.4   123.8 
    Foreign exchange (gain) loss  (1.2)  3.6   26.9   10.6 
    Depreciation and amortization (a)  19.3   20.8   78.0   85.3 
    Goodwill and other asset impairment  —   —   797.9   — 
    Restructuring and other charges (b)  25.3   27.9   49.1   51.2 
    Stock based compensation  14.8   15.3   74.4   57.2 
    Disposition-related costs (c)  1.1   6.1   10.0   13.4 
    One-time spin related costs (d)  1.3   32.1   24.7   130.0 
    Customer matter (e)  —   0.8   —   6.0 
    Enabling Services Segment costs (f)  —   —   —   7.3 
    CEO transition related costs  —   —   5.1   — 
    Other (g)  5.8   2.4   15.4   (7.3)
    Adjusted EBITDA from continuing operations $54.0  $56.0  $189.9  $202.5 



    (a) Includes amortization of intangible assets acquired as part of business acquisitions.

    (b) Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions to reduce overcapacity, align resources and facilities, and restructure certain operations.

    (c) Disposition-related costs are short-term incremental costs to support the transition services agreement associated with the sale of the Enabling Services Segment.

    (d) Represents one-time or incremental costs required to implement capabilities to exit the transition services agreement with the Company's former parent.

    (e) As part of working with a customer, the Company agreed to make concessions and provide discounts and other consideration to the customer as part of a multi-party solution. There were no related adjustments in 2025 as the agreed upon amounts had been satisfied.

    (f) These adjustments remove the impact of certain Enabling Services costs not included in discontinued operations. The Enabling Services Segment was sold in the second quarter of 2024.

    (g) Includes adjustments to estimated contingent consideration on a sale of a facility, income related to services provided under transition services agreements, settlements related to litigation initiated prior to the spinoff of the Company as a standalone company, the yield expense incurred on amounts received under the Company's Receivables Securitization Program, and amortization of implementation costs deferred in connection with cloud computing arrangements.

    FORTREA HOLDINGS INC.

    NET INCOME TO ADJUSTED NET INCOME RECONCILIATION

    (in millions, except per share data)

    (unaudited)

     
      Three Months Ended

    December 31,
     Years Ended

    December 31,
      2025

     2024

     2025

     2024

    Adjusted net income from continuing operations:        
    Net loss from continuing operations $(32.5) $(73.9) $(986.2) $(271.5)
    Foreign exchange (gain) loss  (1.2)  3.6   26.9   10.6 
    Amortization (a)  14.4   15.2   58.3   60.8 
    Goodwill and other asset impairment  —   —   797.9   — 
    Restructuring and other charges (b)  25.3   27.9   49.1   51.2 
    Stock based compensation  14.8   15.3   74.4   57.2 
    Disposition-related costs (c)  1.1   6.1   10.0   13.4 
    One-time spin-related costs (d)  1.3   32.1   24.7   130.0 
    Customer matter (e)  —   0.8   —   6.0 
    Enabling Services Segment costs (f)  —   —   —   7.3 
    CEO transition related costs  —   —   5.1   — 
    Other (g)  5.8   2.4   15.4   (7.3)
    Income tax impact of adjustments (h)  (19.8)  (12.9)  (35.2)  (27.6)
    Adjusted net income from continuing operations $9.2  $16.6  $40.4  $30.1 
             
    Basic shares  92.8   89.7   91.2   89.5 
    Diluted shares  97.1   90.2   93.3   90.3 
    Adjusted basic EPS from continuing operations $0.10  $0.18  $0.44  $0.34 
    Adjusted diluted EPS from continuing operations $0.09  $0.18  $0.43  $0.33 



    (a) Includes amortization of intangible assets acquired as part of business acquisitions.

    (b) Restructuring and other charges represent amounts incurred in connection with the elimination of redundant positions to reduce overcapacity, align resources and facilities, and restructure certain operations.

    (c) Disposition-related costs are short-term incremental costs to support the transition services agreement associated with the sale of the Enabling Services Segment.

    (d) Represents one-time or incremental costs required to implement capabilities to exit the transition services agreement with the Company's former parent.

    (e) As part of working with a customer, the Company agreed to make concessions and provide discounts and other consideration to the customer as part of a multi-party solution. There were no related adjustments in 2025 as the agreed upon amounts had been satisfied.

    (f) These adjustments remove the impact of certain Enabling Services costs not included in discontinued operations. The Enabling Services Segment was sold in the second quarter of 2024.

    (g) Includes adjustments to estimated contingent consideration on a sale of a facility, income related to services provided under transition services agreements, settlements related to litigation initiated prior to the spinoff of the Company as a standalone company, the yield expense incurred on amounts received under the Company's Receivables Securitization Program, and amortization of implementation costs deferred in connection with cloud computing arrangements.

    (h) Income tax impact of adjustments represents the amount of additional tax expense that the Company estimates it would record if it used Non-GAAP results instead of GAAP results in the calculation of its provision.

    FORTREA HOLDINGS INC.

    NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW RECONCILIATION

    (in millions)

    (unaudited)

     
      Year Ended

    December 31, 2025
    Net cash provided by operating activities $113.5 
    Capital expenditures  (25.2)
    Free cash flow $88.3 
         

    The cash flows related to discontinued operations have not been segregated and are included in the consolidated statements of cash flows.



    Primary Logo

    Get the next $FTRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTRE

    DatePrice TargetRatingAnalyst
    1/8/2026$22.00Hold → Buy
    Truist
    1/6/2026$25.00In-line → Outperform
    Evercore ISI
    12/15/2025$15.00Underweight → Equal Weight
    Barclays
    12/11/2025$21.00Neutral → Buy
    Citigroup
    8/4/2025$9.00Neutral → Outperform
    Robert W. Baird
    5/2/2025$7.00Hold
    Truist
    4/10/2025$6.00Equal Weight → Underweight
    Barclays
    12/11/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    More analyst ratings

    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fortrea upgraded by Truist with a new price target

    Truist upgraded Fortrea from Hold to Buy and set a new price target of $22.00

    1/8/26 8:10:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Fortrea from In-line to Outperform and set a new price target of $25.00

    1/6/26 8:26:05 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Barclays with a new price target

    Barclays upgraded Fortrea from Underweight to Equal Weight and set a new price target of $15.00

    12/15/25 9:05:06 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Russell Erin L bought $100,018 worth of shares (9,854 units at $10.15) (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/4/25 4:39:23 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Director Neupert Peter M bought $407,150 worth of shares (62,500 units at $6.51), increasing direct ownership by 175% to 98,132 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    8/11/25 8:21:29 PM ET
    $FTRE
    Medical Specialities
    Health Care

    General Counsel Hanson James S. bought $50,600 worth of shares (2,000 units at $25.30), increasing direct ownership by 37% to 7,475 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/12/24 6:28:42 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Morais Mark A. converted options into 2,255 shares and sold $16,365 worth of shares (1,179 units at $13.88), increasing direct ownership by 2% to 58,052 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    2/11/26 7:04:31 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Chief Financial Officer Mcconnell Jill G. sold $12,229 worth of shares (881 units at $13.88) and converted options into 1,685 shares, increasing direct ownership by 1% to 59,574 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    2/11/26 7:02:25 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 4 filed by Director Sharbaugh William J

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    11/24/25 4:03:48 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    SEC Filings

    View All

    Fortrea Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Fortrea Holdings Inc. (0001965040) (Filer)

    2/26/26 6:05:44 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Fortrea Holdings Inc.

    SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)

    2/17/26 5:06:24 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 144 filed by Fortrea Holdings Inc.

    144 - Fortrea Holdings Inc. (0001965040) (Subject)

    1/20/26 3:30:32 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

    Revenue and Adjusted EBITDA results delivered in line with stated full-year targetsFull‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full yearFourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 monthsGAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full yearAdjusted EBITDA of $54.0 million for the fourth quarter and $189.9 million for the full yearAdjusted net income of $9.2 million, or $0.09 per diluted share for the fourth quarter; $40.4 million, or

    2/26/26 6:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services

    DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea's chief medical officer (CMO) and president of Clinical Pharmacology Services (CPS) is now dedicated to his CMO responsibilities, namely medical strategy, scientific leadership, ethics and governance oversight across Fortrea's portfolio. Scott Dove, PhD joins Fortrea as its new president of CPS, responsible for Fortrea's early clinical development solutions across its global network of clinical research units. Cohen and Dove both serve on Fortrea'

    2/17/26 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call

    DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following ea

    1/29/26 8:08:01 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Leadership Updates

    Live Leadership Updates

    View All

    Fortrea Appoints Agnieszka Gallagher as General Counsel

    DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company's legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea's leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period. "Aggie brings broad and deep executive experience in the life sciences and beyond to Fortrea, with a track record of navigating complexity in global companies," said Anshul Thakral, CEO of Fortrea.

    11/17/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints William Sharbaugh to Board of Directors

    DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company's Board of Directors. Mr. Sharbaugh brings extensive healthcare experience in finance, operations, manufacturing, and quality to the position, having served in executive and board roles during his more than three decades in the pharmaceutical industry. "I'm delighted to welcome Bill to the Fortrea Board, bringing an impressive background in CRO and pharmaceutical operations," said Anshul Thakral, CEO of Fortrea. "He is a highly respected leader, who understands our stakeholders a

    9/22/25 4:30:50 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations

    DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea's global investor relations strategy, serving as a key liaison to the investment community. "Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter," said McConnell. "She brings not only deep capital markets expertise but also integrity, insi

    8/5/25 6:00:02 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Financials

    Live finance-specific insights

    View All

    Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

    Revenue and Adjusted EBITDA results delivered in line with stated full-year targetsFull‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full yearFourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 monthsGAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full yearAdjusted EBITDA of $54.0 million for the fourth quarter and $189.9 million for the full yearAdjusted net income of $9.2 million, or $0.09 per diluted share for the fourth quarter; $40.4 million, or

    2/26/26 6:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call

    DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following ea

    1/29/26 8:08:01 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Reports Third Quarter 2025 Results

    For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 millionGAAP net loss of $(15.9) millionAdjusted EBITDA of $50.7 millionGAAP and adjusted net (loss) income per diluted share of $(0.17) and $0.12, respectivelyBook-to-bill ratio of 1.13x, resulting in 1.07x book-to-bill for the trailing 12 monthsCost saving initiatives remain on trackRaising 2025 revenue guidance to a range of $2,700 million to $2,750 million; narrowing 2025 adjusted EBITDA guidance to a range of $175 million to $195 million DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported

    11/5/25 6:30:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortrea Holdings Inc.

    SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

    11/12/24 9:55:14 AM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    5/28/24 5:10:47 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    2/26/24 7:01:18 PM ET
    $FTRE
    Medical Specialities
    Health Care